Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MAP3K1: A Multifunctional Kinase at the Crossroads of Cancer Progression and Tumor Suppression.

Cells·2026
Same author

Defects in DNA damage signaling and cell cycle checkpoints in a mouse model of Rhno1 deletion.

Cell death discovery·2025
Same author

Synthesis and Characterization of Bisphosphonate-Functionalized Gadolinium Oxide Nanoparticles as Nonionizing Contrast Agents to Detect Bone Turnover.

ACS applied materials & interfaces·2025
Same author

Surveying the Proteome-Wide Landscape of Mitoxantrone and Examining Drug Sensitivity in BRCA1-Deficient Ovarian Cancer Using Quantitative Proteomics.

Proteomes·2025
Same author

CRISPR Targeting the 5' Regulatory Region of FOXM1 Will Also Disrupt RHNO1.

Drug development research·2025
Same author

A Selective MAP3K1 Inhibitor Facilitates Discovery of NPM1 as a Member of the Network.

Molecules (Basel, Switzerland)·2025

Related Experiment Video

Updated: Jun 25, 2025

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.9K

PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives.

Makenzie Vorderbruggen1,2, Carlos A Velázquez-Martínez3, Amarnath Natarajan1,2

  • 1Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, NE 68198-6805, USA.

International Journal of Molecular Sciences
|May 25, 2024
PubMed
Summary

Targeted protein degradation (TPD) using proteolysis-targeting chimeras (PROTACs) offers a novel therapeutic strategy for ovarian cancer. This review explores PROTACs in ovarian cancer models and discusses strategies for selective delivery and improved efficacy.

Keywords:
PROTAChigh-grade serous ovarian cancerovarian cancertargeted protein degradation

More Related Videos

A Coregistered Ultrasound and Photoacoustic Imaging Protocol for the Transvaginal Imaging of Ovarian Lesions
10:21

A Coregistered Ultrasound and Photoacoustic Imaging Protocol for the Transvaginal Imaging of Ovarian Lesions

Published on: March 3, 2023

1.4K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.3K

Related Experiment Videos

Last Updated: Jun 25, 2025

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.9K
A Coregistered Ultrasound and Photoacoustic Imaging Protocol for the Transvaginal Imaging of Ovarian Lesions
10:21

A Coregistered Ultrasound and Photoacoustic Imaging Protocol for the Transvaginal Imaging of Ovarian Lesions

Published on: March 3, 2023

1.4K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Ovarian cancer is a leading cause of gynecologic cancer mortality.
  • Advanced ovarian cancer frequently relapses, with current therapies often lacking curative potential.
  • Novel therapeutic strategies are urgently needed for ovarian cancer treatment.

Purpose of the Study:

  • To review proteolysis-targeting chimeras (PROTACs) investigated in ovarian cancer models.
  • To highlight PROTACs from other cancers with potential ovarian cancer applications.
  • To discuss advancements in selective delivery and pharmacodynamics of PROTACs for ovarian cancer.

Main Methods:

  • Literature review of PROTACs in ovarian cancer research.
  • Analysis of PROTACs studied in other cancer types for potential ovarian cancer utility.
  • Exploration of strategies for targeted delivery and improved pharmacodynamics.

Main Results:

  • Synopsis of current PROTACs tested in ovarian cancer models.
  • Identification of promising PROTAC candidates from other malignancies.
  • Discussion of enabling technologies for PROTACs in ovarian cancer.

Conclusions:

  • PROTACs represent a promising targeted protein degradation approach for ovarian cancer.
  • Further research into selective delivery and optimized pharmacodynamics is crucial for clinical translation.
  • PROTACs hold potential to overcome limitations of existing ovarian cancer therapies.